In a bid to unearth therapeutic avenues for aortic aneurysms, proteasome 20S subunit alpha 4 (PSMA4) and plasminogen activator urokinase (PLAU) were pinpointed to colocalize with aortic aneurysms through MR analysis, suggesting that targeting PLAU and PSMA4 inhibition might curtail the risk of aortic aneurysms [11]. The gene discussed is PSMA4; the disease is aortic aneurysm.